Drug details

Adrucil (fluorouracil injection)

type of Antineoplastics, Antimetabolite

Adrucil (fluorouracil injection) is a nucleoside metabolic inhibitor indicated for the treatment of patients with adenocarcinoma of the colon and rectum, adenocarcinoma of the breast, gastric adenocarcinoma, or pancreatic adenocarcinoma. The brand name Adrucil has been discontinued. It may be available in generic form.

This drug may have the following side effects:

• nausea,
• headache,
• vomiting,
• dry or cracking skin,
• low red and white blood cells and platelets,
• gastrointestinal ulcers,
• severe allergic reaction (anaphylaxis),
• other allergic reactions,
• involuntary eye movement,
• skin sensitivity to sunlight (redness or dark spots on skin),
• tear duct obstruction,
• changes in vision,
• tearing,
• eye sensitivity to light,
  
• euphoria,
• inflammation of veins caused by blood clots,
• nosebleed, and
• nail changes (including loss of nails).

The following drugs are related to Adrucil, either as a replacement or used together:

• Alymsys (bevacizumab-maly injection)
• Avastin (bevacizumab)
• Camptosar Injection (irinotecan hydrochloride)
• Xeloda (capecitabine)
• Erbitux (cetuximab)
• Cyramza (ramucirumab solution for intravenous infusion)
• Eloxatin (oxaliplatin injection)
• Leucovorin Calcium (leucovorin calcium tablets)
• Leucovorin Calcium Injection (leucovorin calcium)
• Lonsurf (trifluridine and tipiracil tablets)
• Vectibix (panitumumab injection for intravenous use)
• Stivarga (regorafenib tablets)
• Zaltrap (ziv-aflibercept injection for intravenous infusion)